Takeda

Artificial Intelligence Gaining Ground in Drug Development
Artificial Intelligence Gaining Ground in Drug Development
BioSpace
CASP
machine learning
artificial intelligence
drug development
Merck
Takeda
Atomwise
Bayer
GSK
Google DeepMind
Recursion Pharmaceuticals
Flag link:
Takeda's Hemophilia A Drug: New Data and a $155 Million Patent Infringement Settlement
Takeda's Hemophilia A Drug: New Data and a $155 Million Patent Infringement Settlement
BioSpace
Takeda
clinical trials
Adynovate
Baxalta
Bayer
patents
Flag link:
Q4 Biopharma Themes: Strong 2018, Weaker 2019 Earnings Projections, Concerns over Drug Pricing
Q4 Biopharma Themes: Strong 2018, Weaker 2019 Earnings Projections, Concerns over Drug Pricing
BioSpace
earnings
Pfizer
Amgen
AbbVie
JNJ
Merck
Novo Nordisk
Takeda
Flag link:
Takeda's Phase III Dengue Vaccine Results Bring Them "One Step Closer" to Stopping Tropical Disease
Takeda's Phase III Dengue Vaccine Results Bring Them "One Step Closer" to Stopping Tropical Disease
BioSpace
Takeda
vaccines
dengue
tropical diseases
Flag link:
Last week in biopharma - earnings reports, drug pricing, a new GENE CEO and more
Last week in biopharma - earnings reports, drug pricing, a new GENE CEO and more
CP Wire
earnings
drug pricing
Genentech
Eli Lilly
Medtronic
Roche
M&A
Takeda
GSK
FDA
Flag link:
Last week in biopharma-earnings reports, drug pricing, a new GENE CEO and more
earnings
drug pricing
Genentech
Eli Lilly
Medtronic
Roche
M&A
Takeda
GSK
FDA
Flag link:
Is the Smoldering NASH Market Ready to Burst Into Flames?
Is the Smoldering NASH Market Ready to Burst Into Flames?
BioSpace
NASH
Allergan
Regeneron
Alnylam
AstraZeneca
Merck
Takeda
Gilead Sciences
Bristol-Myers Squibb
Intercept Pharmaceuticals
Flag link:
Takeda mulling sale of emerging market drugs – report
Takeda mulling sale of emerging market drugs – report
Pharmaforum
Takeda
Shire
M&A
emerging markets
Flag link:
Takeda’s Shire takeover could herald new era of pharma M&A
Takeda’s Shire takeover could herald new era of pharma M&A
Pharmaforum
M&A
Takeda
Shire
taxes
Pfizer
Flag link:
With mega merger season in full swing, Takeda officially swallows Shire
With mega merger season in full swing, Takeda officially swallows Shire
Endpoints
Takeda
Shire
M&A
Flag link:
Takeda to keep consumer business, looks outside Japan for selloffs instead: CEO
Takeda to keep consumer business, looks outside Japan for selloffs instead: CEO
Fierce Pharma
Takeda
Japan
consumer health
Christophe Weber
Flag link:
Takeda builds arsenal for immuno-oncology research, creates cell therapy group
Takeda builds arsenal for immuno-oncology research, creates cell therapy group
Endpoints
Takeda
immuno-oncology
cell therapy
Shire
Flag link:
New Class of Breast Cancer Drugs Could Help Treat Toughest Lung Cancer Cases
New Class of Breast Cancer Drugs Could Help Treat Toughest Lung Cancer Cases
BioSpace
breast cancer
lung cancer
AstraZeneca
Tagrisso
Novartis
Gleevec
Tasigna
Bristol-Myers Squibb
Sprycel
Pfizer
Bosulif
Takeda
Iclusig
Flag link:
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
Flag link:
Shire gears up to battle Allergan's Linzess with new constipation drug Motegrity
Shire gears up to battle Allergan's Linzess with new constipation drug Motegrity
Fierce Pharma
Takeda
Shire
Allergan
chronic idiopathic constipation
Motegrity
Flag link:
Eisai, Takeda and GARDP hunt for new antibiotics
Eisai, Takeda and GARDP hunt for new antibiotics
Pharmaforum
Eisai
Takeda
GARDP
antibiotics
R&D
Flag link:
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Xtalks
clinical trials
Multiple Myeloma
adaptive trial design
AbbVie
Celgene
Eli Lilly
Genentech
Janssen
Takeda
Flag link:
What do Martin Shkreli, Gilead and Takeda have in common? They all figure prominently in the new top-20 list of the world’s most expensive drugs
What do Martin Shkreli, Gilead and Takeda have in common? They all figure prominently in the new top-20 list of the world’s most expensive drugs
Endpoints
Takeda
Gilead Sciences
Martin Shkreli
drug pricing
Flag link:
A last-ditch effort to derail Takeda’s $62B Shire buyout goes down in flames
A last-ditch effort to derail Takeda’s $62B Shire buyout goes down in flames
Endpoints
Takeda
Shire
M&A
Flag link:
Takeda Acquisition Of Shire May Bode Well For R&D Staff
Takeda Acquisition Of Shire May Bode Well For R&D Staff
Forbes
Shire
Takeda
R&D
M&A
Flag link:

Pages